- The trend backdrop is active with a 7-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Activity pressure is positive on the latest completed week.
- Activity pressure is constructive, supporting the smart-money activity read.
TARSONS
NSI
Week ended 07 Aug 2026
Weekly Investor Report
Tarsons Products Limited · Healthcare · Medical Instruments & Supplies
Latest close
312.3 INR
-0.7%
latest week
Weekly setup
Constructive, but selective
The weekly trend is active. Price is 38.4% above the Trend Line and sits at 68.6% of its 52-week range. The latest completed week returned -0.7%, after a 3.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.
Setup score
51
out of 100
Latest Close
312.3 INR
7 Aug 2026
1W Return
-0.7%
latest completed week
4W Return
3.0%
short-term follow-through
12W Return
50.9%
quarterly tape
Trend Breadth
13.5%
7 of 52 weeks active
Volume Ratio
0.3x
vs 13-week average
- Price is below Fair Value, so the market is still discounting the latest tape.
- Next-week expectancy is negative at 42.76% based on similar historical setup states.
- Recent volatility is running well above the one-year baseline.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-0.7%
Latest completed week; four-week move 3.0%.
Indicator stack
32/74
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Recent
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 42.76%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
50/100
22 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is active. Price is 38.4% above the Trend Line and sits at 68.6% of its 52-week range. The latest completed week returned -0.7%, after a 3.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.3x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.6012-week average 0.30
12-week confirmation
Trend active7/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership8/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.60Current proprietary activity-pressure read.
Buy signals2Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is 3.0% over four weeks, 50.9% over 12 weeks, and -12.4% over one year. The current trend has remained active for 7 consecutive weeks.
Performance by holding period
Active trend streak7 weeks
Active weeks in one year7
Trend breadth13.5%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure1.31Latest activity-pressure read.
Pressure change0.1%Four-week change in activity pressure.
Leadership27.85Latest relative-leadership reading.
RS change17.4%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth ranks weakly; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 91%
Model confidence 85%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength9/100Blend of value, momentum, and quality. Underlying universe rank 92; rank 1 is best.
Value24/100Relative valuation strength. Underlying universe rank 77; rank 1 is best.
Quality31/100Profitability and accounting quality. Underlying universe rank 70; rank 1 is best.
Momentum27/100Medium-term price momentum. Underlying universe rank 74; rank 1 is best.
Growth12/100Revenue and earnings growth. Underlying universe rank 89; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Value-quality framework1/100Value and quality alignment from the Sharemaestro SVQF framework.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- 116.0x Price divided by trailing earnings.
- Price / sales
- 3.9x Market value relative to trailing revenue.
- EV / EBITDA
- 14.4x Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -0.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 67.1% Gross profit retained from each unit of revenue.
- Operating margin
- 5.1% Operating profit retained from revenue.
- Free-cash-flow margin
- -1.7% Free cash flow generated from revenue.
- Return on invested capital
- 1.6% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 7.7% Latest one-year revenue growth.
- EPS growth
- -51.9% Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 6/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- 0.0% Net share repurchases relative to market value.
- Shareholder yield
- 0.0% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.6x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 22 relevant articles.
2 positive · 19 neutral · 1 negativePatient CapitalRecent
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-17.8%Distance below the 52-week high.
13-week volatility9.3%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher13 of 2613 weeks finished lower.
Best week+27.9%Week of 19 Jun.
Worst week-9.1%Week of 15 May.
Latest week-0.7%Week of 7 Aug.
Shape of recent returns
Strong gains7
Modest gains6
Flat weeks0
Modest losses7
Sharp losses6
Recent vol9.3%13-week weekly-return volatility.
Base vol6.5%52-week weekly-return volatility.
Up/down split20/32Count of positive and negative weeks in the 52-week window.
Average skew5.8% / -3.7%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorIN Healthcare
4-week rank- / 100
Group average1.2%
Trend breadth83.0%
Trend83.0%active weekly trend signals
MD85.0%positive activity pressure
RS73.0%positive relative leadership
Four-week leaders
IndustryIN Medical Instruments & Supplies
4-week rank3 / 5
Group average4.2%
Trend breadth100.0%
Trend100.0%active weekly trend signals
MD100.0%positive activity pressure
RS60.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape45/100
Trend, activity pressure, participation, and risk combine to a 45/100 tape read.
Indicator analysis67/100Latest 12-week confirmation: trend 7/12, activity pressure 12/12, relative leadership 8/12.
Activity pressure 0.60; No reversal markers Next-Week ExpectancyNegative 42.76%Next-week expectancy is negative with a 42.76% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors21/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 59; Small Cap Core rank 70 SVQF1/100Value and quality alignment from the Sharemaestro SVQF framework.
Composite rank 1566.5 of 1576 Patient CapitalRecentActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
Recent buy signal in the last 8 weeks Sentiment50/100Weighted news tone is neutral across 22 relevant articles.
Tarsons Products schedules investor meet with Emkay Global for Aug 13 Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 312.3 INR | -0.7% | 225.7 INR | 372.4 INR | 1.31 | 27.85 | 624.6K | On |
| 31 Jul 2026 | 314.6 INR | 0.6% | 222.6 INR | 374.1 INR | 1.42 | 29.30 | 533.5K | On |
| 24 Jul 2026 | 312.8 INR | 8.8% | 220.0 INR | 376.0 INR | 1.41 | 31.30 | 7.8M | On |
| 17 Jul 2026 | 287.5 INR | -5.2% | 217.3 INR | 377.8 INR | 1.33 | 17.44 | 1.0M | On |
| 10 Jul 2026 | 303.3 INR | 13.8% | 215.4 INR | 379.7 INR | 1.31 | 23.72 | 11.1M | On |
| 3 Jul 2026 | 266.6 INR | 2.9% | 212.9 INR | 381.8 INR | 1.10 | 7.92 | 107.1K | On |
| 26 Jun 2026 | 259.0 INR | -1.4% | 211.4 INR | 383.9 INR | 1.01 | 4.93 | 0 | On |
| 19 Jun 2026 | 262.6 INR | 27.9% | 210.3 INR | 386.0 INR | 1.04 | 5.73 | 288.8K | Off |
| 12 Jun 2026 | 205.4 INR | -2.6% | 208.8 INR | 388.1 INR | 1.02 | -16.56 | 62.6K | Off |
| 5 Jun 2026 | 210.7 INR | 0.6% | 209.9 INR | 390.5 INR | 1.02 | -14.55 | 27.7K | Off |
| 29 May 2026 | 209.5 INR | -4.2% | 211.9 INR | 392.6 INR | 1.13 | -16.60 | 2.7M | Off |
| 22 May 2026 | 218.7 INR | 5.7% | 214.5 INR | 394.9 INR | 1.10 | -14.52 | 379.0K | Off |
| 15 May 2026 | 206.9 INR | -9.1% | 216.9 INR | 397.2 INR | 1.08 | -19.88 | 304.0K | Off |
| 8 May 2026 | 227.8 INR | 3.6% | 219.7 INR | 399.3 INR | 1.17 | -14.81 | 1.0M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.